Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus THYPINONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus THYPINONE.
AMINOHIPPURATE SODIUM vs THYPINONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
THYPINONE is a synthetic thyrotropin-releasing hormone (TRH) analog that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary. It also has central nervous system effects, potentially modulating neurotransmitter release and exhibiting neuroprotective properties.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
Oral: 5 mg twice daily; intravenous: 2.5 mg bolus followed by 1 mg/hour continuous infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal half-life 8-12 hours; prolonged to 20-30 hours in severe hepatic impairment, requiring dose adjustment
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Renal (70% unchanged), biliary/fecal (25% as glucuronide metabolites), 5% other
Category C
Category C
Diagnostic Agent
Diagnostic Agent